Opinions on Serina and Enable's New Collaboration to Create SER-252 for Parkinson Disease.

Published Date: 02 Jun 2024

The development plans for SER-252, an investigational apomorphine therapy for advanced Parkinson disease, were discussed by Randall Moreadith, MD, PhD, chief development officer of Serina Therapeutics, and Mike Hooven, chairman and CEO of Enable Injections.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot